ClinicalTrials.gg
CompletedNCT06852937Updated Sep 17, 2026

Using da Vinci SP System for Patients With Cholelithiasis and Choledocholithiasis

An interventional study of da Vinci SP Surgery System in Cholelithiasis and Choledocholithiasis, sponsored by National Taiwan University Hospital. Completed at 1 site in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-09-17.

Primary conditionCholedocholithiasisRegistry: CholelithiasisReclassifiedWhy we changed it
Registry
Cholelithiasis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Choledocholithiasis
Why
  1. The study's listed conditions name Choledocholithiasis, a narrower term within Cholelithiasis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by National Taiwan University Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Study summary

A prospective, interventional, single arm study to investigate clinical feasibility of single-stage cholecystectomy and common bile duct exploration using da Vinci SP Surgical System (robotic surgery)

Read the detailed description

Cholelithiasis (gallstones) is a common disease of digestive tract in adults. It has been reported that 5-10% or 2 million of Taiwanese adults have gallstones according to National Health Insurance Administration.

Laparoscopic cholecystectomy is deemed a surgical standard of care for its safety, effectiveness, and benefits: less post-operative pain, faster recovery, shorter hospital stay, and better cosmesis. However, the advantages of da Vinci surgical system include enhanced vision, wristed instruments, and dexterity of control.

Robotic cholecystectomy by single-port SP system is associated with shorter operation time, shorter dissection time, and less post-operative pain.

Further improvement in robotic cholecystectomy with CBDE regarding cosmesis and patient satisfaction could be made by adopting da Vinci SP system which preserves enhanced vision and instrument dexterity with only one access port. So far there is no published data on robotic cholecystectomy with CBDE using da Vinci SP. Current study is set forth to evaluate technical feasibility and clinical outcome of robotic biliary surgery using da Vinci SP Surgical System for patients with complex cholelithiasis.

02

Conditions studied

  • Cholelithiasis
  • Choledocholithiasis

Browse trials for

03

In context

Choledocholithiasis Reclassified

109 studies on the registry are indexed under Choledocholithiasis; 24 are open to participants now.

This study's enrollment of 24 is below the median of 100 across 76 interventional studies indexed under Choledocholithiasis.

Browse Choledocholithiasis studies →

Lead sponsor

National Taiwan University Hospital is the lead sponsor of 2,615 studies on the registry; 576 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.

Compared within Choledocholithiasis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Cholelithiasis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 20 years or more
  2. Symptomatic cholelithiasis with or without choledocholithiasis, symptomatic chronic cholecystitis with or without biliary tract injury or stricture
  3. Indication of cholecystectomy with or without common bile duct exploration and deemed feasible for robotic surgery
  4. Patient not feasible or have failed stone extraction or intervention for choledocholithiasis by endoscopic retrograde cholangiopancreatography for patients with choledocholithiasis could be included
  5. classification 1-2 and adequate organ function
  6. Patients willing and able to comply with study protocol requirements and follow-up
  7. Patients who are taking anti- or anti-coagulation medications are eligible for this trial, but the associated agents should be discontinued 5 days prior to the operation day. Patients who are taking Wafarin should be admitted two days earlier for bridging to Heparin. Other medications for underlying diseases can be taken as usual.
  8. With

Exclusion criteria

Exclusion Criteria:

  1. Severe acute cholecystitis
  2. Suspected biliary tract cancer or untreated biliary tract cancer
  3. ≥35 or BMI \<18.5
  4. Unable to tolerate robotic surgery position
  5. Severe adhesion due to prior abdominopelvic surgery
  6. Prior major upper abdominal surgery judged by the investigator as not feasible for robotic surgery
  7. Active infectious disease
  8. Severe concomitant illness that drastically shortens or increases risk of therapeutic interventions, such as: severe heart disease ( functional class III-IV) or severe lung disease (GOLD Group C-D)
  9. Cannot follow trial-required procedures
  10. Concomitant systemic or pelvic disease that increases the risk of surgery
  11. Patients with coagulopathy
  12. Emergency surgery
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Operation of focus procedure with da Vinci SP Surgery System

    Operation of cholecystectomy and common bile duct exploration with da Vinci SP Surgery System

    Device: da Vinci SP Surgery System

Interventions

  • Deviceda Vinci SP Surgery System

    da Vinci SP Surgery System

06

What researchers measure

Primary outcomes

  1. Incidence of conversion rate

    The primary performance endpoint will be assessed as the ability to successfully completed the planned procedure with da Vinci SP System, with no conversion to alternative surgery including open surgery or laparoscopy.

    Time frame: During Surgery

Secondary outcomes

  1. Incidence of Treatment Emergent Adverse Events

    The safety endpoint will be assessed as the incidence of all intra-operatvie and post-operative adverse events that occur through the follow up period.

    Time frame: up to 6 months

07

Study locations

1 site
  • National Taiwan University Hospital
    Taipei, 100, Taiwan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Feb 2026, 13 months.

Of 41 non-industry interventional studies with no phase under Choledocholithiasis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's 13 months is below that.

Counting every sponsor, half of 43 studies reached it within 21 months; a quarter within 12 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2024
First posted
Feb 28, 2025
StartActual
Dec 21, 2024
Primary completionActual
Feb 5, 2026
CompletionActual
Feb 5, 2026
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06852937
Collaborators
Intuitive Surgical
Responsible party
Sponsor
First posted
Feb 28, 2025
Start date
Dec 21, 2024
Primary completion
Feb 5, 2026
Completion
Feb 5, 2026
Last update
Sep 17, 2026

Study contacts

Yao-Ming Wu
principal investigator · Vice Superintendent of NTUCC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion